These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2732134)

  • 1. Toxicological profile of FCE 22101 and its orally available ester FCE 22891.
    Brughera M; Scampini G; Ferrari ML; Nava A; Mazué G
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():129-35. PubMed ID: 2732134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101.
    Norrby SR; Burman LA; Sassella D; Corigli R; Cassinelli G; Franceschi G; Dornbusch K
    J Antimicrob Chemother; 1990 Mar; 25(3):371-83. PubMed ID: 2338416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative neurotoxicity of benzylpenicillin, imipenem/cilastatin and FCE 22101, a new injectible penem.
    Schliamser SE; Broholm KA; Liljedahl AL; Norrby SR
    J Antimicrob Chemother; 1988 Nov; 22(5):687-95. PubMed ID: 3209527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary bladder hyperplasia in the rat: non-specific pathogenetic considerations using a beta-lactam antibiotic.
    Iatropoulos MJ; Newman AJ; Dayan AD; Brughera M; Scampini G; Mazue G
    Exp Toxicol Pathol; 1994 Oct; 46(4-5):265-74. PubMed ID: 7894235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes associated with long-term oral administration of the penem antibiotic FCE 22891 to rats and monkeys with particular emphasis on the urinary tract and the urine.
    Brughera M; Iatropoulos MJ; Scampini G; Moneta D; Mazué G; Newman AJ
    Toxicol Pathol; 1995; 23(1):34-46. PubMed ID: 7770698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety evaluation of meropenem in animals: studies on the kidney.
    Topham JC; Murgatroyd LB; Jones DV; Goonetilleke UR; Wright J
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():287-306. PubMed ID: 2681127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antimicrobial spectrum of FCE 22101 and its orally available ester FCE 22891.
    Franceschi G; Perrone E; Alpegiani M; Bedeschi A; Battistini C; Zarini F; Della Bruna C
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():1-6. PubMed ID: 2659569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo evaluation of the penem FCE 22101 and its orally absorbed ester FCE 22891.
    Bruna CD; Jabes D; Sebben G; Sanfilippo A
    G Ital Chemioter; 1983; 30(2-3):125-30. PubMed ID: 6329870
    [No Abstract]   [Full Text] [Related]  

  • 9. The disposition and urinary metabolism of 14C-labelled FCE 22891, a pro-drug of FCE 22101, in animals.
    Battaglia R; Benedetti MS; Frigerio E; Vicario G; Roncucci R
    J Antimicrob Chemother; 1990 Jan; 25(1):133-9. PubMed ID: 2318748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of FCE 22101 in man following different modes of administration.
    Lovering AM; White LO; Lewis DA; MacGowan AP; Routh KR; Pickin DM; Reeves DS
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():179-95. PubMed ID: 2732141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro interaction between the penem FCE 22101 and ceftazidime.
    Barry AL; Jones RN
    Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):807-9. PubMed ID: 3145870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of two new carbapenems FCE 22101 and CGP 31608 in comparison with imipenem.
    Van der Auwera P; Ernst F; Grenier P; Glupczynski Y; Husson M; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):179-89. PubMed ID: 3478328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics.
    Neu HC; Chin NX; Labthavikul P
    J Antimicrob Chemother; 1985 Sep; 16(3):305-13. PubMed ID: 2997100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative inhibitory and bactericidal activities of FCE 22101 against gram-positive cocci and anaerobes in vitro.
    Maskell JP; Tang T; Asad S; Williams JD
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():65-74. PubMed ID: 2732145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of FCE 22101 and other beta-lactam antibiotics against experimental genital infections in the rat and mouse.
    Castellani P; Meinardi G; Della Bruna C
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():157-63. PubMed ID: 2732137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial activity of FCE 22101 against relatively resistant blood culture isolates.
    Qadri SM; Ueno Y; Ellis ME
    Chemotherapy; 1991; 37(1):15-22. PubMed ID: 2013238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of a new penem FCE 22101.
    Hoban DJ
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():53-7. PubMed ID: 2786518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure to imipenem/cilastatin causes nephrotoxicity and even urolithiasis in Wistar rats.
    Tahri A; Lahyani A; Kallel R; Ayadi F; Boudawara T; Sahnoun Z
    Toxicology; 2018 Jul; 404-405():59-67. PubMed ID: 29775647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of [14C]FCE 22891, a penem antibiotic, following oral administration to healthy volunteers.
    Efthymiopoulos C; Strolin Benedetti M; Sassella D; Boobis A; Davies D
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1958-63. PubMed ID: 1416887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of FCE 22101 and synergy studies with other antimicrobial agents.
    Chin NX; Neu HC
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():95-101. PubMed ID: 2786520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.